Menveo

Meningococcal Group Y Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm197 Protein, the active ingredient in Menveo, is a vaccine presented as an injectable solution for intramuscular use. It is indicated to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W‑135 and Y in at‑risk populations, including adolescents, travelers and individuals with certain medical conditions.

GNH USA supplies Menveo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides cold‑chain logistics for global distribution.

Menveo is a conjugate vaccine that targets meningococcal polysaccharides to prevent invasive disease. - Meningococcal disease (serogroups A, C, W‑135, Y): Provides active immunity to prevent invasive infection caused by Neisseria meningitidis. - Adolescents and young adults: Reduces risk of meningococcal disease in high‑risk age groups. - Travelers to endemic regions: Offers protection against meningococcal disease during international travel.

Common Side Effects: - Injection site pain: Mild to moderate discomfort at the injection site. - Redness: Localized erythema around the injection area. - Fever: Transient elevation of body temperature. - Headache: Mild headache occurring within 24‑48 hours.

Serious or Rare Side Effects: - Anaphylaxis: Severe allergic reaction requiring immediate medical attention. - Seizure: Rare occurrence of convulsive episodes post‑vaccination. - Severe allergic reaction: Includes angioedema or bronchospasm.

Precautions should be observed before administering Menveo. - Screen for hypersensitivity: Do not vaccinate individuals with known allergy to any vaccine component. - Delay vaccination: Postpone if the person has a moderate or severe acute illness. - Pregnancy: Use only when the expected benefit justifies the potential risk. - Concurrent vaccines: May be co‑administered with other vaccines according to immunization schedules. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Vaccination may be influenced by other therapies. Major Interactions (Avoid): - Live attenuated vaccines: Avoid simultaneous administration; separate by at least 4 weeks. - Immunoglobulin therapy: May reduce vaccine response; avoid within 2 weeks of vaccination. Moderate Interactions (Monitor Closely): - Antibiotics: May slightly diminish immune response; no dose adjustment required. - Immunosuppressive therapy: May lower antibody production; monitor serologic response. - Antipyretics: May mask post‑vaccination fever; use as needed.